George Poste

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search

George Henry Poste, CBE FRS, is a former Director of the Biodesign Institute at Arizona State University.


Dr. George Poste is the Del E. Webb Professor of Health Innovation and Chief Scientist at The Complex Adaptive Systems Initiative (CASI) ( at Arizona State University (ASU). This program integrates research in genomics, synthetic biology and high-performance computing to study the altered regulation of molecular networks in human diseases to develop new diagnostic tests for precision medicine and the remote monitoring of health status using miniaturized body sensors and mobile devices. He assumed this post in 2009. From 2003 to 2009 he directed and built the Biodesign Institute at ASU. He has published more than 350 research papers and edited 14 books on pharmaceutical technologies, cancer and infectious diseases. He has received honorary degrees in science, law and medicine for his research contributions.

In addition to his academic post, He serves as the Chief Executive of Health Technology Networks ( which provides consulting services in pharmaceutical R&D, oncology and national security. He is a Member of the Board of Directors of Exelixis, Caris Life Sciences, and the Scientific Advisory Boards of the A. Alfred Taubman Medical Research Institute at the University of Michigan, Synthetic Genomics, Vir Biotechnology, iNanoBio, Haplogen GmbH (Vienna) and MediSix (Singapore). From 1992 to 1999, he was Chief Science and Technology Officer and President, R&D, of SmithKline Beecham (SB) (now GlaxoSmithKilne). During his tenure at SB, he was associated with the successful registration of multiple drug, vaccine and diagnostic products. He has served on the Board of Directors of Structural Genomix (acquired by Lilly), Orchid Biosciences (acquired by LapCorp), diaDexus (acquired by Vaxgen), Monsanto (acquired by Bayer) and Advanced PCS (acquired by CVS-Caremark).

He was named “R&D Scientist of the Year” by R&D Magazine (2004), received the Einstein award from the Global Business Leadership Council (2006), the Scrip Lifetime Achievement award voted by the leadership of the global pharmaceutical industry (2009), and the Lifetime Achievement award from the Arizona BioIndustry Association (2016).

He is a Fellow of the U.K. Royal Society, the Royal College of Pathologists and the U.K. Academy of Medicine, a member of the Council for Foreign Relations, the US Academy of Medicine Global Forum on Infectious Disease and the Blue Ribbon Commission on Biodefense. He is a former Distinguished Fellow at the Hoover Institution at Stanford University and a Governor of the Bulletin of Atomic Scientists. He is a past member of the Defense Science Board of the U.S. Department of Defense. Currently, he serves on advisory committees for several U.S. government agencies in defense, intelligence, national security and healthcare.

History and schooling[edit]

Educated in the United Kingdom at Bexhill-on-Sea Grammar school and the University of Bristol.

Honours and awards[edit]

Dr. Poste has received honorary doctorates in law and science for his contributions to international health policy and is board certified in pathology.

He was elected a Fellow of the Royal Society in 1997.[1] He was appointed CBE in the 1999 New Year Honours.

He is a Fellow of the UK Academy of Medicine, The Royal College of Pathologists and a Member of the Council for Foreign Relations.


  1. ^ "Fellows of the Royal Society". Royal Society. Retrieved 2012-08-03.

External links[edit]